Evidence map›Paper›PMID 40232042›Full record

ArticleCancer reports (Hoboken, N.J.)2025

Tailored Therapeutic Approach in a Patient With Diffuse Large B-Cell Lymphoma With Meningeal Infiltration, Concurrent Classic Hodgkin Lymphoma, and Smoldering Multiple Myeloma: A Case Report.

Giusy Ceparano, Daniele Lorenzini, Maurilio Ponzoni, Giorgia Levati, Davide Epifania, Vincenzo Marasco

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Karyotype evolution of multiple myeloma.Journal of clinical and experimental hematopathology : JCEH · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Giusy CeparanoDepartment of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0009-0002-5475-5161
Daniele LorenziniDepartment of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-1425-3354
Maurilio PonzoniPathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Giorgia LevatiDepartment of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Davide EpifaniaDepartment of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Vincenzo MarascoDepartment of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoexisting primary hematologic malignancies in untreated multiple myeloma (MM) are rare. CASE: A 69-year-old man with smoldering multiple myeloma (sMM) presented with lymphadenopathies and an intracranial mass. He was diagnosed with diffuse large B-cell lymphoma (DLBCL), classic Hodgkin lymphoma (cHL), and sMM. The patient received R-CHOP and R-ICE, followed by autologous stem cell transplantation, achieving complete remission of DLBCL and cHL, and very good partial remission of MM.

conclusionThis case illustrates the complexity of managing multiple malignancies and the importance of a tailored therapeutic approach.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHodgkin DiseaseLymphoma, Large B-Cell, DiffuseNeoplasms, Multiple PrimarySmoldering Multiple MyelomaAgedCyclophosphamideDoxorubicinHumansMalePrednisoneRituximabTransplantation, AutologousTreatment OutcomeVincristineCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineconcurrent neoplasmsdiffuse large B‐cell lymphomaHodgkin lymphomamultiple myelomatailored therapeutic approach

Identifiers

PMID40232042
PMCPMC11998167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.